Financial reports
10-Q
2024 Q2
Quarterly report
8 Aug 24
10-Q
2024 Q1
Quarterly report
9 May 24
10-K
2023 FY
Annual report
22 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
23 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
Current reports
8-K
Departure of Directors or Certain Officers
12 Aug 24
8-K
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
8 Aug 24
8-K
Amendments to Articles of Incorporation or Bylaws
10 Jun 24
8-K
Entry into a Material Definitive Agreement
10 May 24
8-K
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
9 May 24
8-K
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
7 May 24
8-K
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
22 Feb 24
8-K
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
19 Jan 24
8-K
Results of Operations and Financial Condition
19 Jan 24
8-K
Results of Operations and Financial Condition
9 Nov 23
Registration and prospectus
S-3ASR
Automatic shelf registration
10 May 24
S-8
Registration of securities for employees
9 May 24
424B5
Prospectus supplement for primary offering
19 Jan 24
S-3MEF
Registration of additional securities for an S-3
19 Jan 24
424B3
Prospectus supplement
19 Jan 24
424B5
Prospectus supplement for primary offering
16 Jun 23
S-8
Registration of securities for employees
11 May 23
424B5
Prospectus supplement for primary offering
14 Sep 22
424B5
Prospectus supplement for primary offering
13 Sep 22
424B5
Prospectus supplement for primary offering
5 May 22
Proxies
DEFA14A
Additional proxy soliciting materials
7 May 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
PRE 14A
Preliminary proxy
15 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
2 May 22
DEF 14A
Definitive proxy
2 May 22
Other
EFFECT
Notice of effectiveness
6 May 22
CORRESP
Correspondence with SEC
3 May 22
UPLOAD
Letter from SEC
8 Apr 22
EFFECT
Notice of effectiveness
26 Mar 21
CERT
Certification of approval for exchange listing
25 Mar 21
CORRESP
Correspondence with SEC
22 Mar 21
CORRESP
Correspondence with SEC
22 Mar 21
CORRESP
Correspondence with SEC
8 Mar 21
UPLOAD
Letter from SEC
12 Jan 21
Ownership
4
Alan J Russell
24 Sep 24
4
JOHN R MOORE
24 Sep 24
4
Joanne M. Donovan
24 Sep 24
4
Behrad Derakhshan
24 Sep 24
4
R Michael Carruthers
24 Sep 24
SC 13D/A
Novo Holdings A/S
23 Sep 24
144
Notice of proposed sale of securities
23 Sep 24
144
Notice of proposed sale of securities
20 Sep 24
144
Notice of proposed sale of securities
20 Sep 24
144
Notice of proposed sale of securities
20 Sep 24